{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T20:48:02Z","timestamp":1770238082951,"version":"3.49.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13555-025-01606-9","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T17:07:08Z","timestamp":1764954428000},"page":"637-646","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK Analysis"],"prefix":"10.1007","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct03624127","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03611751","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-8707","authenticated-orcid":false,"given":"April W.","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-6481","authenticated-orcid":false,"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7789-6915","authenticated-orcid":false,"given":"Howard","family":"Sofen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7330-4713","authenticated-orcid":false,"given":"Lynda","family":"Spelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misti","family":"Linaberry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Ming","family":"Jou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolin","family":"Daamen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa B.","family":"Kimball","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"1606_CR1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw1736","volume":"11","author":"JR Burke","year":"2019","unstructured":"Burke JR, Cheng L, Gillooly KM, Strnad J, Zupa-Fernandez A, Catlett IM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019;11:eaaw1736.","journal-title":"Sci Transl Med"},{"key":"1606_CR2","unstructured":"Sotyktu [package insert]. Princeton: Bristol Myers Squibb; 2022."},{"key":"1606_CR3","unstructured":"Sotyktu [European summary of product characteristics]. Dublin: Bristol Myers Squibb EEIG; 2023."},{"key":"1606_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Tha\u00e7i D, et al. Deucravacitinib versus placebo and apremilast in moderate-to-severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88:29\u201339.","journal-title":"J Am Acad Dermatol"},{"key":"1606_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober B, Tha\u00e7i D, Sofen H, Kircik L, Gordon KB, Foley P, et al. Deucravacitinib versus placebo and apremilast in moderate-to-severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, program for evaluation of TYK2 inhibitor psoriasis second phase 3 trial. J Am Acad Dermatol. 2023;88:40\u201351.","journal-title":"J Am Acad Dermatol"},{"key":"1606_CR6","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","volume":"83","author":"P Schafer","year":"2012","unstructured":"Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583\u201390.","journal-title":"Biochem Pharmacol"},{"key":"1606_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate-to-severe plaque psoriasis: results of a phase III, randomized, controlled trial (efficacy and safety trial evaluating the effects of apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37\u201349.","journal-title":"J Am Acad Dermatol"},{"key":"1606_CR8","doi-asserted-by":"publisher","first-page":"645","DOI":"10.36849\/JDD.8293","volume":"23","author":"L Kircik","year":"2024","unstructured":"Kircik L, Aldredge LM, DiRuggiero D. Selective tyrosine kinase 2 (TYK2) inhibition in plaque psoriasis. J Drugs Dermatol. 2024;23:645\u201352.","journal-title":"J Drugs Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01606-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01606-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01606-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:40:31Z","timestamp":1770190831000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01606-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1606"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01606-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"April W. Armstrong has served as a research investigator, scientific advisor, and\/or speaker for AbbVie, Almirall, Arcutis, Aslan, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, EPI Health, Incyte, Janssen, LEO Pharma, Lilly, Mindera Health, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB. Richard B. Warren is an Editor-in-Chief of\n                      Dermatology and Therapy\n                      and was not involved in the selection of peer reviewers for this manuscript nor any of the subsequent editorial decisions. Professor Warren has received research grants from AbbVie, Almirall, Amgen, Celgene, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, and UCB and consulting fees from AbbVie, Almirall, Amgen, Astellas, Boehringer Ingelheim, Celgene, DICE Therapeutics, GSK, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi, UCB, and Union Therapeutics. Howard Sofen has served as a clinical investigator for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, LEO Pharma, Lilly, Novartis, and Sun Pharma. Lynda Spelman has served as a consultant, paid investigator, clinical advisory board member and\/or speaker for AbbVie, Amgen, Anacor, AnaptysBio, Ascend, Astellas, AstraZeneca, Blaze Bioscience, Boehringer Ingelheim, Botanix, Bristol Myers Squibb, Celgene, ConnectBiopharma, Genesis Care, Dermira, Eli Lilly, Enkang Pharmaceuticals, Equillium, Evelo Biosciences, Genesis Care, Galderma, Genentech, GlaxoSmithKline, Hexima, Incyte, InflaRx GmbH, Invion, Janssen, Kiniksa Pharmaceuticals, Kobio Labs, LG Chem, Lipidio Pharma, LEO Pharma, Mayne, Medimmune, Merck, Merck-Serono, Novartis, Nektar Therapeutics, Olix Pharmaceuticals, Otsuka, Pfizer, Phosphagenics, Photon MD, Principia, Regeneron, Ribon, Samumed, Sanofi Genzyme, SHR, Sun Pharma, Takeda, UCB, and Zai Lab. Misti Linaberry, Brandon Becker, and Ying-Ming Jou are employees of and shareholders in Bristol Myers Squibb. Carolin Daamen was an employee of and shareholder in Bristol Myers Squibb at the time of study conduct. Alexa B. Kimball\u2019s institution received grants from AbbVie, AnaptysBio, Bristol Myers Squibb, Eli Lilly, Incyte, Janssen, MoonLake Immunotherapeutics, Novartis, Pfizer, Prometheus, Sanofi, Sonoma Biotherapeutics, and UCB; she received consulting fees from AbbVie, Boehringer Ingelheim, Eli Lilly, Janssen, MoonLake Immunotherapeutics, Novartis, Takeda, Target RWE, UCB, Union Therapeutics, and Ventyx; and serves on the board of directors of Almirall.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The POETYK PSO-1 and PSO-2 trials were conducted in accordance with Good Clinical Practice, as defined by the International Council for Harmonization and Declaration of Helsinki. Independent institutional review board approvals were obtained and all participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}